ReGen Sues FDA Over Menaflex Clearance Repeal

Law360, New York (June 1, 2011, 5:02 PM EDT) -- ReGen Biologics Inc. sued the U.S. Food and Drug Administration in Washington on Tuesday, alleging that the agency's rescission of marketing clearance for its Menaflex collagen meniscus implant was unlawful and ultimately forced the company into bankruptcy.

The FDA originally classified the Menaflex device — used for the repair and reinforcement of the meniscal tissue in the knee — as a Class II device under the Federal Food, Drug, and Cosmetic Act in December 2008, after concluding that it was substantially equivalent to other legally marketed...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

REGEN BIOLOGICS, INC. v. SEBELIUS et al


Case Number

1:11-cv-01006

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

Rudolph Contreras

Date Filed

May 31, 2011

Law Firms

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.